若年性黄斑変性（JMD）の上市済みおよびパイプライン薬剤評価、臨床試験、競合情勢

対象16カ国において、2023年の若年性黄斑変性（JMD）の診断済罹患件数は555,110例以上と予測されています。JMD治療領域では、市販されている治療薬が不足しているため、アンメットクリニカルニーズが大きくなっています。JMD領域の研究開発活動は非常に限られており、開発中期から後期段階にあるパイプライン医薬品はわずか6品目です。JMDの臨床試験活動は過去10年間非常に限られており、全体で26件の試験が実施されたのみです。

当レポートは、若年性黄斑変性（JMD）治療薬の現在および将来の競合情勢について、データに基づいた概要を提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 疾病の情勢

• 疾病の概要
• 疫学の概要
• 治療の概要

第4章 市販薬の評価

第5章 価格設定と償還の評価

第6章 パイプライン医薬品の評価

• 第Ⅲ相パイプライン医薬品
• 開発段階別の概要
• 分子タイプ別の概要
• 作用機序別の概要
• 投与経路別の概要
• 医薬品特異的相転移成功率（PTSR）と承認の可能性（LoA）
• 治療領域および適応症固有のPTSRおよびLoA

第7章 臨床試験の評価

• 歴史的概要
• フェーズ別の概要
• ステータスごとの概要
• 進行中および計画中の試験のフェーズ別の概要
• 仮想コンポーネントを使用したトライアル
• 地理的概要
• 地域別の単一国および多国籍試験
• 上位20のスポンサーとフェーズ別の内訳
• 上位20スポンサーのステータス別の内訳
• エンドポイントステータスごとの概要
• 人種および民族別の概要
• 登録データ
• 治験サイトの上位20か国
• 世界のトップ20サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第8章 取引の情勢

• 地域別の合併、買収、戦略的提携
• 最近の合併、買収、戦略的提携

第9章 商業的評価

• 主要な市場参入企業

第10章 将来の市場促進要因

第11章 付録

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in JMD therapeutics.

• More than 555,110 diagnosed prevalent cases of JMD are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for JMD.
• There are significant unmet clinical need in the JMD treatment space due to a lack of marketed therapies.
• R&D activity in the JMD space is very limited, with only six pipeline drugs in the mid-to-late-stage of development.
• Clinical trial activity in JMD has been very limited during the past 10 years, with only 26 trials conducted overall.

Scope

GlobalData's Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the JMD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global JMD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

5 Pricing and Reimbursement Assessment

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer